CCM
YMAB

Consonance Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Consonance Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,073
Closed -$301K – 43
2020
Q4 		$301K Buy
+6,073
New +$281K 0.03% 38

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Consonance Capital Management's YMAB Position: Q1 2021 in Review

Consonance Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2021, closing a stake of 6,073 shares — an estimated $301K sold.

Consonance Capital Management first reported a position in YMAB in Q4 2020 and held it in 1 quarter. The position peaked at $301K in Q4 2020. 117 funds tracked by Wall St. Rank hold YMAB as of Q1 2021.

  • Consonance Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Consonance Capital Management sold 6,073 Y-mAbs Therapeutics shares in Q1 2021, an estimated $301K.
  • Consonance Capital Management first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 1 quarter.
  • Consonance Capital Management's Y-mAbs Therapeutics position peaked at $301K in Q4 2020.
  • 117 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2021.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.